Standalone and consolidated Q1 FY27 results show sequential and year-over-year declines in revenue and profit, with CRDMO and Speciality Ingredients segments contributing to overall performance. 1.67 million shares were allotted under ESOP 2024.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.